FDA gave nivolumab (Opdivo) an accelerated approval for the treatment of patients 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
